News

BDEGP Creates 598 New Jobs in the State

Wednesday, February 02, 2011

 
Colorado's Bioscience Discovery Evaluation Grant Program Creates 598 New Jobs in the State, with Payroll Exceeding $44 million 

Colorado bioscience program creates 598 jobs

Wednesday, February 02, 2011

 

Colorado's Bioscience Discovery Evaluation Grant Program has created 598 jobs in the state, with payroll exceeding $44 million, according to the Colorado BioScience Association and the Colorado Office of Economic Development and International Trade.

Appropriated funding to date for the program has totaled $14 million; $10.8 million has been awarded as of August 2010, and $5.5 million has been appropriated for each of the next two years, said Holli Baumunk, the association's president and chief executive.

Another $68 million has been leveraged through follow-on investment, grants and matching funds, providing 8.3 times the state's funding, Baumunk said.

"Bioscience continues to play a critical role in the growth of Colorado's knowledge-based economy," Baumunk said.

http://www.denverpost.com/business/ci_17270132

Read more: Colorado bioscience program creates 598 jobs - The Denver Post http://www.denverpost.com/business/ci_17270132#ixzz1CpCa1k90
Read The Denver Post's Terms of Use of its content: http://www.denverpost.com/termsofuse  
Continue Reading

Boilerplate

Tuesday, February 01, 2011

About the Colorado BioScience Association
The Colorado BioScience Association (CBSA) is a not-for-profit corporation providing services and support for Colorado's growing biosciences industry. With more than 350 members, CBSA actively works to promote the growth of the industry by working for a better business environment, grow the state's biotech workforce, advocate for policies that support a strong bioscience industry in the state, and speak with a single voice on behalf of the industry. For more information, visit http://www.cobioscience.com.  

Encision reports financials

Monday, January 31, 2011

Encision Inc. (Boulder) reported profitable financial results for its third fiscal quarter ended December 31, 2010.  The Company recorded net income of $234,000 or $0.04 per share for the third quarter of fiscal year 2011 on net sales of $2.917 million, representing a slight increase in net sales from our second quarter ended September 30, 2010, and a 10.5% decrease from net sales of $3.260 million for the third quarter of fiscal year 2010.
http://www.prnewswire.com/news-releases/encision-reports-profitable-third-quarter-results-114922199.html 

Taligen Therapeutics acquired for $111M

Monday, January 31, 2011

Taligen Therapeutics Inc. has been acquired by Alexion Pharmaceuticals Inc., a Connecticut therapeutics firm, for $111 million in an up front cash payment. 

CORHIO awarded $1.7M

Friday, January 28, 2011

CORHIO, the Colorado Regional Health Information Organization, has been awarded $1.7 million by the Health Information Exchange (HIE) Challenge Grant Program run by the Office of the National Coordinator for Health IT (ONC). CORHIO was selected for innovation in the area of care improvement and cost reduction for patients transitioning between hospitals, long-term care facilities and other post-acute care providers. The Challenge Grant allows CORHIO to support long-term and post-acute care providers in Boulder, Colorado Springs, Pueblo and the San Luis Valley as they work to implement processes to improve care transitions to and from hospitals in their communities.
http://www.prnewswire.com/news-releases/corhio-awarded-17m-grant-to-improve-care-coordination-for-hospital-and-long-term-care-patients-114816929.html  

2011 BioScience Day at the Capitol

Thursday, January 27, 2011

Media Advisory
Join us for the 3rd Annual BioScience Day at the Capitol BioBreakfast. Hear from our state legislators on their preview for the 2011 legislative session, learn about the CBSA's proposed legislation helping the bioscience industry, and listen as BIO describes the federal healthcare plan and other national issues impacting the industry. 

CBSA on Radio Colorado Network

Thursday, January 27, 2011

CBSA's President & CEO Holli Baumunk interviewed on the Radio Colorado Network's Business for Breakfast Show

CBSA President & CEO Holli Baumunk interviewed on the Radio Colorado Network's Business for Breakfast broadcast this morning, discussing the association's legislative initiatives and how the CBSA is accelerating life science growth in the state. She interviewed with Business For Breakfast Co-Host Woody Vincent.

KRCN-AM 1060 is the flagship station of the Radio Colorado Network (RNC). RCN is the only full-time "Business Talk" radio station serving the greater Denver, Fort Collins, and Cheyenne WY communities. The network is also found on KVLE-AM 610 Vail/Aspen, KWYD AM 1580 Colorado Springs-Pueblo and KSKE 1450 Buena Vista, plus online at http://www.radioconetwork.com/radio/stream.html.

 

Link to listen to the Holli Baumunk interview

(approximately 10 minutes)

You can subscribe to the Business For Breakfast podcast rss feed at:

http://www.radioconetwork.com/rss/b4brss2.xml

 

 

 

 
Continue Reading

Covidien delivers 20,000th ForceTriad

Wednesday, January 26, 2011

Covidien (Boulder) announced the delivery of the Company's 20,000th ForceTriad™ energy platform. The Dongzhimen Hospital, an affiliate of Beijing University of Chinese Medicine, in Beijing, China, took delivery of the device earlier this month. Known for its teaching and clinical research, Dongzhimen Hospital embraces both Chinese and Western medicine in serving the healthcare needs of its patients and the community. Since its launch in 2006, the ForceTriad platform has been placed into service in hospitals in 94 countries.
http://www.businesswire.com/news/home/20110126006666/en/Covidien-Delivers-20000th-ForceTriadTM-Energy-Platform  

Inviragen announces MOU

Wednesday, January 26, 2011

Inviragen, Inc. (Fort Collins) and the Duke-National University of Singapore Graduate Medical School ("Duke-NUS") announced today that they have completed a memorandum of understanding (MOU) to establish a partnership between the two organizations. The goal of the partnership is to better understand how emerging infectious diseases are transmitted and how transmission can be prevented. Through this collaborative program, Inviragen and Duke-NUS aim to advance the research and development of vaccines against infectious diseases such as dengue fever, hand, foot and mouth disease and chikungunya.
http://www.businesswire.com/news/home/20110126007091/en/Inviragen-Duke-NUS-Form-Collaborative-Vaccine-Research-Development